Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock
NYSE · COAG
37.97
Fundamentals
Market cap
$1.92B
Price / Earnings ratio
-30.1x
Price / Sales ratio
N/A
Price / Book ratio
4.2x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Hemab Therapeutics Holdings, Inc. Common Stock
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. The company aims to advance treatment approaches for bleeding and thrombotic diseases through the discovery, development, and potential commercialization of innovative therapeutics. Its strategy is centered on addressing significant unmet medical needs among patients globally who are affected by serious coagulation-related conditions
SectorHealthcare
IndustryBiotechnology
Employees59
CEODr. Benny Sorensen M.D., Ph.D.
IPO DateMay 1, 2026
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Benny Sorensen M.D., Ph.D. | President, CEO & Director | 1974 |
| Mr. Mads Nikolaj Behrndt-Eriksen M.Sc. | CFO & GM | 1983 |
| Dr. Catherine Eilleen Madigan M.D. | Chief Medical Officer | 1972 |
| Dr. Ananthram Sreenivasa Murthy M.Sc., Ph.D. | Chief Operating Officer | 1978 |
| Ms. Karen Weisbach | Chief People & Culture Officer | — |
| Ms. Cecile Bonvoisin M.Sc. | Senior Vice President of CMC & Manufacturing | — |
| Ms. Tara O'Meara | Senior Vice President of Development Operations | — |
Fundamentals
Valuation
Market cap$1.92B
Price-to-sales ratioN/A
Price-to-book value4.24
Price-earnings ratio-30.10
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-67.56
Income Statement
Average volume576,144
EBITDA$-63.26M
1 year high (52w)$55.42
1 year low (52w)$23.00
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



